Postmenopausal osteoporosis and osteopenia are chronic and uncurable conditions that invariably lead to an increased risk of vertebral, hip, and femoral neck fracture if left untreated. Clinical guidelines establish, in general, pharmacological combinations allied to lifestyle changes as the mainstay of their management, and also increasing bone marrow density, lowering fracture risk, and improving quality of life are their main therapeutic goals. The objective of this systematic review was to analyze the available data in the scientific medical literature regarding the role of the ibandronate and cholecalciferol combination in postmenopausal osteoporosis and osteopenia management. Based on our results, we concluded that the above combination is safe and feasible for the clinical control of both conditions.
References
[1]
Frampton, J.E. and Perry, C.M. (2008) Ibandronate: A Review of Its Use in the Management of Postmenopausal Osteoporosis. Drugs, 68, 2683-2707. https://doi.org/10.2165/0003495-200868180-00011
[2]
Hasan, W.N.W., Chin, K.Y., Jolly, J.J., et al. (2018) Identifying Potential Therapeutics for Osteoporosis by Exploiting the Relationship between Mevalonate Pathway and Bone Metabolism. Endocrine, Metabolic and Immune Disorders—Drug Targets, 18, 450-457. https://doi.org/10.2174/1871530318666180423122409
[3]
LeBoff, M.S., Greenspan, S.L., Insogna, K.L., et al. (2022) The Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporosis International, 33, 2049-2102. https://doi.org/10.1007/s00198-021-05900-y
[4]
Maraka, S. and Kennel, K.A. (2015) Bisphosphonates for the Prevention and Treatment of Osteoporosis. BMJ, 351, h3783. https://doi.org/10.1136/bmj.h3783
Selçuk, A.A. (2019) A Guide for Systematic Reviews: PRISMA. Turkish Archives of Otorhinolaryngology, 57, 57-58. https://doi.org/10.5152/tao.2019.4058
[7]
Chesnut III, C.H. (2006) Treating Osteoporosis with Bisphosphonates and Addressing Adherence: A Review of Oral Ibandronate. Drugs, 66, 1351-1359. https://doi.org/10.2165/00003495-200666100-00004
[8]
Ali, N., Jurczyluk, J., Shay, G., et al. (2015) A Highly Sensitive Prenylation Assay Reveals in Vivo Effects of Bisphosphonate Drug on the Rab Prenylome of Macrophages outside the Skeleton. Small GTPases, 6, 202-211. https://doi.org/10.1080/21541248.2015.1085485
[9]
drugbank.com (2022) Vitamin D3: Uses, Interactions, Mechanism of Action. https://go.drugbank.com/drugs/DB00169
[10]
Vieth, R. (2020) Vitamin D Supplementation: Cholecalciferol, Calcifediol, and Calcitriol. The European Journal of Clinical Nutrition, 74, 1493-1497. https://doi.org/10.1038/s41430-020-0697-1
[11]
Holick, M.F. (2017) The Vitamin D Deficiency Pandemic: Approaches for Diagnosis, Treatment and Prevention. Reviews in Endocrine and Metabolic Disorders, 18, 153-165. https://doi.org/10.1007/s11154-017-9424-1
[12]
Jeon, J.-Y., Lee, S.Y., Im, Y.-J., et al. (2014) Comparison of the Pharmacokinetics, Safety, and Tolerability of Vitamin D3 in DP-R206 (150-mg Ibandronate/24,000-IU Vitamin D3 Tablet) and as Monotherapy (24,000 IU) in Healthy Male Korean Adults. Clinical Therapeutics, 36, 48-57. https://doi.org/10.1016/j.clinthera.2013.12.001
[13]
Cho, I.J., Chung, H.Y., Kim, S.W., et al. (2015) Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosis. Endocrinology and Metabolism (Seoul), 30, 272-279. https://doi.org/10.3803/EnM.2015.30.3.272
[14]
Yoon, S.H. (2017) A Monthly Combined Agent of Ibandronate and Cholecalciferol Is Effective in Bone Metabolism but Not in Muscle Strength and Bone Mineral Density in Korean Postmenopausal Women with Osteoporosis. Maturitas, 100, 158. https://doi.org/10.1016/j.maturitas.2017.03.142
[15]
Binkley, N., Silverman, S.L., Simonelli, C., et al. (2009) Monthly Ibandronate Suppresses Serum CTX-I within 3 Days and Maintains a Monthly Fluctuating Pattern of Suppression. Osteoporosis International, 20, 1595-1601. https://doi.org/10.1007/s00198-008-0827-4
[16]
Binkley, N., Martens, M.G., Silverman, S.L., et al. (2009) Improved GI Tolerability with Monthly Ibandronate in Women Previously Using Weekly Bisphosphonates. Southern Medical Journal, 102, 486-492. https://doi.org/10.1097/SMJ.0b013e31819ed0dd
[17]
Bock, O., Börst, H., Beller, G., et al. (2012) Impact of Oral Ibandronate 150 mg Once Monthly on Bone Structure and Density in Postmenopausal Osteoporosis or Osteopenia Derived from in Vivo μCT. Bone, 50, 317-324. https://doi.org/10.1016/j.bone.2011.10.027
[18]
Bonnick, S.L., Silverman, S., Tanner, S.B., et al. (2009) Patient Satisfaction in Postmenopausal Women Treated with a Weekly Bisphosphonate Transitioned to Once-Monthly Ibandronate. Journal of Women’s Health (Larchmt), 18, 935-943. https://doi.org/10.1089/jwh.2008.1064
[19]
Chapurlat, R.D., Laroche, M., Thomas, T., et al. (2013) Effect of Oral Monthly Ibandronate on Bone Microarchitecture in Women with Osteopenia—A Randomized Placebo-Controlled Trial. Osteoporosis International, 24, 311-320. https://doi.org/10.1007/s00198-012-1947-4
[20]
Emkey, R., Koltun, W., Beusterien, K., et al. (2005) Patient Preference for Once-Monthly Ibandronate versus Once-Weekly Alendronate in a Randomized, Open-Label, Cross-Over Trial: The Boniva Alendronate Trial in Osteoporosis (BALTO). Current Medical Research and Opinion, 21, 1895-1903. https://doi.org/10.1185/030079905X74862
[21]
Emkey, R., Delmas, P.D., Bolognese, M., et al. (2009) Efficacy and Tolerability of Once-Monthly Oral Ibandronate (150 mg) and Once-Weekly Oral Alendronate (70 mg): Additional Results from the Monthly Oral Therapy with Ibandronate for Osteoporosis Intervention (MOTION) Study. Clinical Therapeutics, 31, 751-761. https://doi.org/10.1016/j.clinthera.2009.04.018
[22]
Engelke, K., Fuerst, T., Enslin, M.B., et al. (2009) Regional Differences of Spinal BMD Changes after One Year Once-Monthly Ibandronate as Measured by 3D QCT. Journal of Clinical Densitometry, 12, 120. https://doi.org/10.1016/j.jocd.2008.07.076
[23]
Engelke, K., Fuerst, T., Dasic, G., et al. (2010) Regional Distribution of Spine and Hip QCT BMD Responses after One Year of Once-Monthly Ibandronate in Postmenopausal Osteoporosis. Bone, 46, 1626-1632. https://doi.org/10.1016/j.bone.2010.03.003
[24]
Lewiecki, E.M., Keaveny, T.M., Kopperdahl, D.L., et al. (2009) Once-Monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women with Postmenopausal Osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 94, 171-180. https://doi.org/10.1210/jc.2008-1807
[25]
McClung, M.R., Bolognese, M.A., Sedarati, F., et al. (2009) Efficacy and Safety of Monthly Oral Ibandronate in the Prevention of Postmenopausal Bone Loss. Bone, 44, 418-422. https://doi.org/10.1016/j.bone.2008.09.011
[26]
Miller, P.D., McClung, M.R., Macovei, L., et al. (2005) Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results from the MOBILE Study. Journal of Bone and Mineral Research, 20, 1315-1322. https://doi.org/10.1359/JBMR.050313
[27]
Miller, P.D., Epstein, S., Sedarati, F., et al. (2008) Once-Monthly Oral Ibandronate Compared with Weekly Oral Alendronate in Postmenopausal Osteoporosis: Results from the Head-to-Head MOTION Study. Current Medical Research and Opinion, 24, 207-213. https://doi.org/10.1185/030079908X253889
[28]
Miller, P.D., Recker, R.R., Reginster, J.-Y., et al. (2012) Efficacy of Monthly Oral Ibandronate Is Sustained over 5 Years: The MOBILE Long-Term Extension Study. Osteoporosis International, 23, 1747-1756. https://doi.org/10.1007/s00198-011-1773-0
[29]
Nakamura, T., Mizunuma, H., Itabashi, A., et al. (2007) Monthly Oral Ibandronate Is Well Tolerated and Efficacious in Japanese Osteoporotic Subjects. Journal of Bone and Mineral Research, 22, S333.
[30]
Reginster, J.-Y., Adami, S., Lakatos, P., et al. (2006) Efficacy and Tolerability of Once-Monthly Oral Ibandronate in Postmenopausal Osteoporosis: 2 Year Results from the MOBILE Study. Annals of Rheumatic Diseases, 65, 654-661. https://doi.org/10.1136/ard.2005.044958
[31]
Stakkestad, J.A., Lakatos, P., Lorenc, R., et al. (2008) Monthly Oral Ibandronate Is Effective and Well Tolerated after 3 Years: The MOBILE Long-Term Extension. Clinical Rheumatology, 27, 955-960. https://doi.org/10.1007/s10067-007-0824-6
